Compare First Trust NASDAQ 100 Technology Index Fund (QTEC) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust NASDAQ 100 Technology Index Fund vs ResMed Inc. — how do they compare? First Trust NASDAQ 100 Technology Index Fund trades at $306.13, while ResMed Inc. trades at $193.21 (market cap $28.40B). The key difference: ResMed Inc. pays a 1.23% dividend while First Trust NASDAQ 100 Technology Index Fund pays none, and First Trust NASDAQ 100 Technology Index Fund is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| QTEC | RMD | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $335.74 | $293.73 |
52-Week Low | $207.03 | $182.82 |
Market Cap | — | $28.40B |
Enterprise Value | — | $27.58B |
Dividend Yield | — | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QTEC, the First Trust NASDAQ-100-Technology Sector ETF, trades at $301.50, up 0.53% on the day. The technical outlook is bearish, with moving averages signaling a downtrend and key support at $285. Recent news highlights its role as a smart beta ETF providing broad technology sector exposure since its 2006 launch, though some reports question if recent large sales signal caution around overheated AI and chip stocks.
The ETF's outlook is clouded by bearish technicals and sector concentration risks, but its equal-weighted access to top tech firms offers targeted exposure. Key risks include market volatility and sector-specific headwinds, while the neutral oscillator readings suggest potential for stabilization near current levels.
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
